Department of Neurological Sciences, Federico II University, Via Pansini 5, Naples, Italy.
Neurol Sci. 2011 Apr;32(2):287-92. doi: 10.1007/s10072-011-0483-x. Epub 2011 Feb 10.
The identification of predictive factors of NAbs development might have a relevant impact on clinical practice. Our objective is to look after predictive factors of NAbs development in MS IFN Beta-1b-treated patients. Database was screened for patients on IFN Beta-1b treatment with an Expanded Disability Status Scale (EDSS) at a baseline between 1 and 3.5, disease duration shorter than 15 years, and NAbs analysis performed every 6 months. The NAbs positive status was analysed in relation to baseline clinical, neuropsychological and brain imaging measures. Forty-nine patients were included. Sixteen patients had become NAbs positive at some point on IFN therapy (35%). NAbs producers differed from not producers for higher incidence of cognitive deficit and higher lesion load (OR = 5.0 and 5.6, respectively). Our study suggests that NAbs development might be a marker of a more aggressive disease and that worse outcome in NAbs producers might be biased by baseline condition.
识别 NAbs 发展的预测因素可能对临床实践具有重要影响。我们的目的是观察 MS IFN Beta-1b 治疗患者中 NAbs 发展的预测因素。对接受 IFN Beta-1b 治疗的患者进行了数据库筛查，这些患者在基线时的扩展残疾状况量表（EDSS）为 1 到 3.5，疾病持续时间短于 15 年，并且每隔 6 个月进行一次 NAbs 分析。分析了 NAbs 阳性状态与基线临床、神经心理学和脑成像测量的关系。共纳入 49 名患者。16 名患者在 IFN 治疗过程中的某个时间点出现了 NAbs 阳性（35%）。产生 NAbs 的患者与不产生 NAbs 的患者相比，认知缺陷和病变负荷的发生率更高（OR 分别为 5.0 和 5.6）。我们的研究表明，NAbs 的发展可能是疾病更具侵袭性的标志，而在 NAbs 产生者中更差的结果可能受到基线条件的影响。
